Cargando…
Revisiting cardiovascular risk reduction in type 2 diabetes and dyslipidemia
Statin therapy has been a mainstay of cardiovascular disease (CVD) risk reduction for the past 20 years in type 2 diabetes management. Its application has been largely due to well-designed, randomized-control studies consistently showing 25–35% CVD risk reduction. However, the remaining 65–75% reduc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434405/ https://www.ncbi.nlm.nih.gov/pubmed/36060284 http://dx.doi.org/10.1016/j.ijcrp.2022.200141 |